Global Drugs for Treating Metabolic Disorders Market Insights, Forecast to 2029

TABLE OF CONTENTS

1 Study Coverage

• 1.1 Drugs for Treating Metabolic Disorders Product Introduction
• 1.2 Market by Type
  • 1.2.1 Global Drugs for Treating Metabolic Disorders Market Size Growth Rate by Type, 2018 VS 2022 VS 2029
  • 1.2.2 Antidiabetic Drugs
  • 1.2.3 Antihypertensive Drugs
  • 1.2.4 Hypolipidemic Drugs
  • 1.2.5 Others
• 1.3 Market by Application
  • 1.3.1 Global Drugs for Treating Metabolic Disorders Market Size Growth Rate by Application, 2018 VS 2022 VS 2029
  • 1.3.2 Hospital
  • 1.3.3 Pharmacy
• 1.4 Assumptions and Limitations
• 1.5 Study Objectives
• 1.6 Years Considered

2 Executive Summary

• 2.1 Global Drugs for Treating Metabolic Disorders Sales Estimates and Forecasts 2018-2029
• 2.2 Global Drugs for Treating Metabolic Disorders Revenue by Region
  • 2.2.1 Global Drugs for Treating Metabolic Disorders Revenue by Region: 2018 VS 2022 VS 2029
  • 2.2.2 Global Drugs for Treating Metabolic Disorders Revenue by Region (2018-2023)
  • 2.2.3 Global Drugs for Treating Metabolic Disorders Revenue by Region (2024-2029)
  • 2.2.4 Global Drugs for Treating Metabolic Disorders Revenue Market Share by Region (2018-2029)
• 2.3 Global Drugs for Treating Metabolic Disorders Sales Estimates and Forecasts 2018-2029
• 2.4 Global Drugs for Treating Metabolic Disorders Sales by Region
  • 2.4.1 Global Drugs for Treating Metabolic Disorders Sales by Region: 2018 VS 2022 VS 2029
  • 2.4.2 Global Drugs for Treating Metabolic Disorders Sales by Region (2018-2023)
  • 2.4.3 Global Drugs for Treating Metabolic Disorders Sales by Region (2024-2029)
  • 2.4.4 Global Drugs for Treating Metabolic Disorders Sales Market Share by Region (2018-2029)
• 2.5 US & Canada
• 2.6 Europe
• 2.7 China
• 2.8 Asia (excluding China)
• 2.9 Middle East, Africa and Latin America

3 Competition by Manufactures

• 3.1 Global Drugs for Treating Metabolic Disorders Sales by Manufacturers
  • 3.1.1 Global Drugs for Treating Metabolic Disorders Sales by Manufacturers (2018-2023)
  • 3.1.2 Global Drugs for Treating Metabolic Disorders Sales Market Share by Manufacturers (2018-2023)
  • 3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Drugs for Treating Metabolic Disorders in 2022
• 3.2 Global Drugs for Treating Metabolic Disorders Revenue by Manufacturers
  • 3.2.1 Global Drugs for Treating Metabolic Disorders Revenue by Manufacturers (2018-2023)
  • 3.2.2 Global Drugs for Treating Metabolic Disorders Revenue Market Share by Manufacturers (2018-2023)
  • 3.2.3 Global Top 10 and Top 5 Companies by Drugs for Treating Metabolic Disorders Revenue in 2022
• 3.3 Global Key Players of Drugs for Treating Metabolic Disorders, Industry Ranking, 2021 VS 2022 VS 2023
• 3.4 Global Drugs for Treating Metabolic Disorders Sales Price by Manufacturers
• 3.5 Analysis of Competitive Landscape
  • 3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
  • 3.5.2 Global Drugs for Treating Metabolic Disorders Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
• 3.6 Global Key Manufacturers of Drugs for Treating Metabolic Disorders, Manufacturing Base Distribution and Headquarters
• 3.7 Global Key Manufacturers of Drugs for Treating Metabolic Disorders, Product Offered and Application
• 3.8 Global Key Manufacturers of Drugs for Treating Metabolic Disorders, Date of Enter into This Industry
• 3.9 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type

• 4.1 Global Drugs for Treating Metabolic Disorders Sales by Type
  • 4.1.1 Global Drugs for Treating Metabolic Disorders Historical Sales by Type (2018-2023)
  • 4.1.2 Global Drugs for Treating Metabolic Disorders Forecasted Sales by Type (2024-2029)
  • 4.1.3 Global Drugs for Treating Metabolic Disorders Sales Market Share by Type (2018-2029)
• 4.2 Global Drugs for Treating Metabolic Disorders Revenue by Type
  • 4.2.1 Global Drugs for Treating Metabolic Disorders Historical Revenue by Type (2018-2023)
  • 4.2.2 Global Drugs for Treating Metabolic Disorders Forecasted Revenue by Type (2024-2029)
  • 4.2.3 Global Drugs for Treating Metabolic Disorders Revenue Market Share by Type (2018-2029)
• 4.3 Global Drugs for Treating Metabolic Disorders Price by Type
  • 4.3.1 Global Drugs for Treating Metabolic Disorders Price by Type (2018-2023)
  • 4.3.2 Global Drugs for Treating Metabolic Disorders Price Forecast by Type (2024-2029)

5 Market Size by Application

• 5.1 Global Drugs for Treating Metabolic Disorders Sales by Application
  • 5.1.1 Global Drugs for Treating Metabolic Disorders Historical Sales by Application (2018-2023)
  • 5.1.2 Global Drugs for Treating Metabolic Disorders Forecasted Sales by Application (2024-2029)
  • 5.1.3 Global Drugs for Treating Metabolic Disorders Sales Market Share by Application (2018-2029)
• 5.2 Global Drugs for Treating Metabolic Disorders Revenue by Application
  • 5.2.1 Global Drugs for Treating Metabolic Disorders Historical Revenue by Application (2018-2023)
  • 5.2.2 Global Drugs for Treating Metabolic Disorders Forecasted Revenue by Application (2024-2029)
  • 5.2.3 Global Drugs for Treating Metabolic Disorders Revenue Market Share by Application (2018-2029)
• 5.3 Global Drugs for Treating Metabolic Disorders Price by Application
  • 5.3.1 Global Drugs for Treating Metabolic Disorders Price by Application (2018-2023)
  • 5.3.2 Global Drugs for Treating Metabolic Disorders Price Forecast by Application (2024-2029)

6 US & Canada

• 6.1 US & Canada Drugs for Treating Metabolic Disorders Market Size by Type
  • 6.1.1 US & Canada Drugs for Treating Metabolic Disorders Sales by Type (2018-2029)
  • 6.1.2 US & Canada Drugs for Treating Metabolic Disorders Revenue by Type (2018-2029)
• 6.2 US & Canada Drugs for Treating Metabolic Disorders Market Size by Application
  • 6.2.1 US & Canada Drugs for Treating Metabolic Disorders Sales by Application (2018-2029)
  • 6.2.2 US & Canada Drugs for Treating Metabolic Disorders Revenue by Application (2018-2029)
• 6.3 US & Canada Drugs for Treating Metabolic Disorders Market Size by Country
  • 6.3.1 US & Canada Drugs for Treating Metabolic Disorders Revenue by Country: 2018 VS 2022 VS 2029
  • 6.3.2 US & Canada Drugs for Treating Metabolic Disorders Sales by Country (2018-2029)
  • 6.3.3 US & Canada Drugs for Treating Metabolic Disorders Revenue by Country (2018-2029)
  • 6.3.4 US
  • 6.3.5 Canada

7 Europe

• 7.1 Europe Drugs for Treating Metabolic Disorders Market Size by Type
  • 7.1.1 Europe Drugs for Treating Metabolic Disorders Sales by Type (2018-2029)
  • 7.1.2 Europe Drugs for Treating Metabolic Disorders Revenue by Type (2018-2029)
• 7.2 Europe Drugs for Treating Metabolic Disorders Market Size by Application
  • 7.2.1 Europe Drugs for Treating Metabolic Disorders Sales by Application (2018-2029)
  • 7.2.2 Europe Drugs for Treating Metabolic Disorders Revenue by Application (2018-2029)
• 7.3 Europe Drugs for Treating Metabolic Disorders Market Size by Country
  • 7.3.1 Europe Drugs for Treating Metabolic Disorders Revenue by Country: 2018 VS 2022 VS 2029
  • 7.3.2 Europe Drugs for Treating Metabolic Disorders Sales by Country (2018-2029)
  • 7.3.3 Europe Drugs for Treating Metabolic Disorders Revenue by Country (2018-2029)
  • 7.3.4 Germany
  • 7.3.5 France
  • 7.3.6 U.K.
  • 7.3.7 Italy
  • 7.3.8 Russia

8 China

• 8.1 China Drugs for Treating Metabolic Disorders Market Size
  • 8.1.1 China Drugs for Treating Metabolic Disorders Sales (2018-2029)
  • 8.1.2 China Drugs for Treating Metabolic Disorders Revenue (2018-2029)
• 8.2 China Drugs for Treating Metabolic Disorders Market Size by Application
  • 8.2.1 China Drugs for Treating Metabolic Disorders Sales by Application (2018-2029)
  • 8.2.2 China Drugs for Treating Metabolic Disorders Revenue by Application (2018-2029)

9 Asia (excluding China)

• 9.1 Asia Drugs for Treating Metabolic Disorders Market Size by Type
  • 9.1.1 Asia Drugs for Treating Metabolic Disorders Sales by Type (2018-2029)
  • 9.1.2 Asia Drugs for Treating Metabolic Disorders Revenue by Type (2018-2029)
• 9.2 Asia Drugs for Treating Metabolic Disorders Market Size by Application
  • 9.2.1 Asia Drugs for Treating Metabolic Disorders Sales by Application (2018-2029)
  • 9.2.2 Asia Drugs for Treating Metabolic Disorders Revenue by Application (2018-2029)
• 9.3 Asia Drugs for Treating Metabolic Disorders Sales by Region
  • 9.3.1 Asia Drugs for Treating Metabolic Disorders Revenue by Region: 2018 VS 2022 VS 2029
  • 9.3.2 Asia Drugs for Treating Metabolic Disorders Revenue by Region (2018-2029)
  • 9.3.3 Asia Drugs for Treating Metabolic Disorders Sales by Region (2018-2029)
  • 9.3.4 Japan
  • 9.3.5 South Korea
  • 9.3.6 China Taiwan
  • 9.3.7 Southeast Asia
  • 9.3.8 India

10 Middle East, Africa and Latin America

• 10.1 Middle East, Africa and Latin America Drugs for Treating Metabolic Disorders Market Size by Type
  • 10.1.1 Middle East, Africa and Latin America Drugs for Treating Metabolic Disorders Sales by Type (2018-2029)
  • 10.1.2 Middle East, Africa and Latin America Drugs for Treating Metabolic Disorders Revenue by Type (2018-2029)
• 10.2 Middle East, Africa and Latin America Drugs for Treating Metabolic Disorders Market Size by Application
  • 10.2.1 Middle East, Africa and Latin America Drugs for Treating Metabolic Disorders Sales by Application (2018-2029)
  • 10.2.2 Middle East, Africa and Latin America Drugs for Treating Metabolic Disorders Revenue by Application (2018-2029)
• 10.3 Middle East, Africa and Latin America Drugs for Treating Metabolic Disorders Sales by Country
  • 10.3.1 Middle East, Africa and Latin America Drugs for Treating Metabolic Disorders Revenue by Country: 2018 VS 2022 VS 2029
  • 10.3.2 Middle East, Africa and Latin America Drugs for Treating Metabolic Disorders Revenue by Country (2018-2029)
  • 10.3.3 Middle East, Africa and Latin America Drugs for Treating Metabolic Disorders Sales by Country (2018-2029)
  • 10.3.4 Brazil
  • 10.3.5 Mexico
  • 10.3.6 Turkey
  • 10.3.7 Israel
  • 10.3.8 GCC Countries

11 Company Profiles

• 11.1 Novo Nordisk
  • 11.1.1 Novo Nordisk Company Information
  • 11.1.2 Novo Nordisk Overview
  • 11.1.3 Novo Nordisk Drugs for Treating Metabolic Disorders Sales, Price, Revenue and Gross Margin (2018-2023)
  • 11.1.4 Novo Nordisk Drugs for Treating Metabolic Disorders Product Model Numbers, Pictures, Descriptions and Specifications
  • 11.1.5 Novo Nordisk Recent Developments
• 11.2 Sanofi
  • 11.2.1 Sanofi Company Information
  • 11.2.2 Sanofi Overview
  • 11.2.3 Sanofi Drugs for Treating Metabolic Disorders Sales, Price, Revenue and Gross Margin (2018-2023)
  • 11.2.4 Sanofi Drugs for Treating Metabolic Disorders Product Model Numbers, Pictures, Descriptions and Specifications
  • 11.2.5 Sanofi Recent Developments
• 11.3 Eli Lilly and Company
  • 11.3.1 Eli Lilly and Company Company Information
  • 11.3.2 Eli Lilly and Company Overview
  • 11.3.3 Eli Lilly and Company Drugs for Treating Metabolic Disorders Sales, Price, Revenue and Gross Margin (2018-2023)
  • 11.3.4 Eli Lilly and Company Drugs for Treating Metabolic Disorders Product Model Numbers, Pictures, Descriptions and Specifications
  • 11.3.5 Eli Lilly and Company Recent Developments
• 11.4 AstraZeneca
  • 11.4.1 AstraZeneca Company Information
  • 11.4.2 AstraZeneca Overview
  • 11.4.3 AstraZeneca Drugs for Treating Metabolic Disorders Sales, Price, Revenue and Gross Margin (2018-2023)
  • 11.4.4 AstraZeneca Drugs for Treating Metabolic Disorders Product Model Numbers, Pictures, Descriptions and Specifications
  • 11.4.5 AstraZeneca Recent Developments
• 11.5 Merck
  • 11.5.1 Merck Company Information
  • 11.5.2 Merck Overview
  • 11.5.3 Merck Drugs for Treating Metabolic Disorders Sales, Price, Revenue and Gross Margin (2018-2023)
  • 11.5.4 Merck Drugs for Treating Metabolic Disorders Product Model Numbers, Pictures, Descriptions and Specifications
  • 11.5.5 Merck Recent Developments
• 11.6 Johnson & Johnson
  • 11.6.1 Johnson & Johnson Company Information
  • 11.6.2 Johnson & Johnson Overview
  • 11.6.3 Johnson & Johnson Drugs for Treating Metabolic Disorders Sales, Price, Revenue and Gross Margin (2018-2023)
  • 11.6.4 Johnson & Johnson Drugs for Treating Metabolic Disorders Product Model Numbers, Pictures, Descriptions and Specifications
  • 11.6.5 Johnson & Johnson Recent Developments
• 11.7 Boehringer Ingelheim
  • 11.7.1 Boehringer Ingelheim Company Information
  • 11.7.2 Boehringer Ingelheim Overview
  • 11.7.3 Boehringer Ingelheim Drugs for Treating Metabolic Disorders Sales, Price, Revenue and Gross Margin (2018-2023)
  • 11.7.4 Boehringer Ingelheim Drugs for Treating Metabolic Disorders Product Model Numbers, Pictures, Descriptions and Specifications
  • 11.7.5 Boehringer Ingelheim Recent Developments
• 11.8 Gilead Sciences
  • 11.8.1 Gilead Sciences Company Information
  • 11.8.2 Gilead Sciences Overview
  • 11.8.3 Gilead Sciences Drugs for Treating Metabolic Disorders Sales, Price, Revenue and Gross Margin (2018-2023)
  • 11.8.4 Gilead Sciences Drugs for Treating Metabolic Disorders Product Model Numbers, Pictures, Descriptions and Specifications
  • 11.8.5 Gilead Sciences Recent Developments

12 Industry Chain and Sales Channels Analysis

• 12.1 Drugs for Treating Metabolic Disorders Industry Chain Analysis
• 12.2 Drugs for Treating Metabolic Disorders Key Raw Materials
  • 12.2.1 Key Raw Materials
  • 12.2.2 Raw Materials Key Suppliers
• 12.3 Drugs for Treating Metabolic Disorders Production Mode & Process
• 12.4 Drugs for Treating Metabolic Disorders Sales and Marketing
  • 12.4.1 Drugs for Treating Metabolic Disorders Sales Channels
  • 12.4.2 Drugs for Treating Metabolic Disorders Distributors
• 12.5 Drugs for Treating Metabolic Disorders Customers

13 Market Dynamics

• 13.1 Drugs for Treating Metabolic Disorders Industry Trends
• 13.2 Drugs for Treating Metabolic Disorders Market Drivers
• 13.3 Drugs for Treating Metabolic Disorders Market Challenges
• 13.4 Drugs for Treating Metabolic Disorders Market Restraints

14 Key Findings in The Global Drugs for Treating Metabolic Disorders Study

15 Appendix

• 15.1 Research Methodology
  • 15.1.1 Methodology/Research Approach
  • 15.1.2 Data Source
• 15.2 Author Details
• 15.3 Disclaimer

List of Tables

• Table 1. Global Drugs for Treating Metabolic Disorders Market Size Growth Rate by Type, 2018 VS 2022 VS 2029 (US$ Million)
• Table 2. Major Manufacturers of Antidiabetic Drugs
• Table 3. Major Manufacturers of Antihypertensive Drugs
• Table 4. Major Manufacturers of Hypolipidemic Drugs
• Table 5. Major Manufacturers of Others
• Table 6. Global Drugs for Treating Metabolic Disorders Market Size Growth Rate by Application, 2018 VS 2022 VS 2029 (US$ Million)
• Table 7. Global Drugs for Treating Metabolic Disorders Revenue Grow Rate (CAGR) by Region: 2018 VS 2022 VS 2029 (US$ Million)
• Table 8. Global Drugs for Treating Metabolic Disorders Revenue by Region (2018-2023) & (US$ Million)
• Table 9. Global Drugs for Treating Metabolic Disorders Revenue by Region (2024-2029) & (US$ Million)
• Table 10. Global Drugs for Treating Metabolic Disorders Revenue Market Share by Region (2018-2023)
• Table 11. Global Drugs for Treating Metabolic Disorders Revenue Market Share by Region (2024-2029)
• Table 12. Global Drugs for Treating Metabolic Disorders Sales Grow Rate (CAGR) by Region: 2018 VS 2022 VS 2029 (US$ Million)
• Table 13. Global Drugs for Treating Metabolic Disorders Sales by Region (2018-2023) & (K Units)
• Table 14. Global Drugs for Treating Metabolic Disorders Sales by Region (2024-2029) & (K Units)
• Table 15. Global Drugs for Treating Metabolic Disorders Sales Market Share by Region (2018-2023)
• Table 16. Global Drugs for Treating Metabolic Disorders Sales Market Share by Region (2024-2029)
• Table 17. Global Drugs for Treating Metabolic Disorders Sales by Manufacturers (2018-2023) & (K Units)
• Table 18. Global Drugs for Treating Metabolic Disorders Sales Share by Manufacturers (2018-2023)
• Table 19. Global Drugs for Treating Metabolic Disorders Revenue by Manufacturers (2018-2023) & (US$ Million)
• Table 20. Global Drugs for Treating Metabolic Disorders Revenue Share by Manufacturers (2018-2023)
• Table 21. Global Key Players of Drugs for Treating Metabolic Disorders, Industry Ranking, 2021 VS 2022 VS 2023
• Table 22. Drugs for Treating Metabolic Disorders Price by Manufacturers 2018-2023 (US$/Unit)
• Table 23. Global Drugs for Treating Metabolic Disorders Manufacturers Market Concentration Ratio (CR5 and HHI)
• Table 24. Global Drugs for Treating Metabolic Disorders by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Drugs for Treating Metabolic Disorders as of 2022)
• Table 25. Global Key Manufacturers of Drugs for Treating Metabolic Disorders, Manufacturing Base Distribution and Headquarters
• Table 26. Global Key Manufacturers of Drugs for Treating Metabolic Disorders, Product Offered and Application
• Table 27. Global Key Manufacturers of Drugs for Treating Metabolic Disorders, Date of Enter into This Industry
• Table 28. Mergers & Acquisitions, Expansion Plans
• Table 29. Global Drugs for Treating Metabolic Disorders Sales by Type (2018-2023) & (K Units)
• Table 30. Global Drugs for Treating Metabolic Disorders Sales by Type (2024-2029) & (K Units)
• Table 31. Global Drugs for Treating Metabolic Disorders Sales Share by Type (2018-2023)
• Table 32. Global Drugs for Treating Metabolic Disorders Sales Share by Type (2024-2029)
• Table 33. Global Drugs for Treating Metabolic Disorders Revenue by Type (2018-2023) & (US$ Million)
• Table 34. Global Drugs for Treating Metabolic Disorders Revenue by Type (2024-2029) & (US$ Million)
• Table 35. Global Drugs for Treating Metabolic Disorders Revenue Share by Type (2018-2023)
• Table 36. Global Drugs for Treating Metabolic Disorders Revenue Share by Type (2024-2029)
• Table 37. Drugs for Treating Metabolic Disorders Price by Type (2018-2023) & (US$/Unit)
• Table 38. Global Drugs for Treating Metabolic Disorders Price Forecast by Type (2024-2029) & (US$/Unit)
• Table 39. Global Drugs for Treating Metabolic Disorders Sales by Application (2018-2023) & (K Units)
• Table 40. Global Drugs for Treating Metabolic Disorders Sales by Application (2024-2029) & (K Units)
• Table 41. Global Drugs for Treating Metabolic Disorders Sales Share by Application (2018-2023)
• Table 42. Global Drugs for Treating Metabolic Disorders Sales Share by Application (2024-2029)
• Table 43. Global Drugs for Treating Metabolic Disorders Revenue by Application (2018-2023) & (US$ Million)
• Table 44. Global Drugs for Treating Metabolic Disorders Revenue by Application (2024-2029) & (US$ Million)
• Table 45. Global Drugs for Treating Metabolic Disorders Revenue Share by Application (2018-2023)
• Table 46. Global Drugs for Treating Metabolic Disorders Revenue Share by Application (2024-2029)
• Table 47. Drugs for Treating Metabolic Disorders Price by Application (2018-2023) & (US$/Unit)
• Table 48. Global Drugs for Treating Metabolic Disorders Price Forecast by Application (2024-2029) & (US$/Unit)
• Table 49. US & Canada Drugs for Treating Metabolic Disorders Sales by Type (2018-2023) & (K Units)
• Table 50. US & Canada Drugs for Treating Metabolic Disorders Sales by Type (2024-2029) & (K Units)
• Table 51. US & Canada Drugs for Treating Metabolic Disorders Revenue by Type (2018-2023) & (US$ Million)
• Table 52. US & Canada Drugs for Treating Metabolic Disorders Revenue by Type (2024-2029) & (US$ Million)
• Table 53. US & Canada Drugs for Treating Metabolic Disorders Sales by Application (2018-2023) & (K Units)
• Table 54. US & Canada Drugs for Treating Metabolic Disorders Sales by Application (2024-2029) & (K Units)
• Table 55. US & Canada Drugs for Treating Metabolic Disorders Revenue by Application (2018-2023) & (US$ Million)
• Table 56. US & Canada Drugs for Treating Metabolic Disorders Revenue by Application (2024-2029) & (US$ Million)
• Table 57. US & Canada Drugs for Treating Metabolic Disorders Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
• Table 58. US & Canada Drugs for Treating Metabolic Disorders Revenue by Country (2018-2023) & (US$ Million)
• Table 59. US & Canada Drugs for Treating Metabolic Disorders Revenue by Country (2024-2029) & (US$ Million)
• Table 60. US & Canada Drugs for Treating Metabolic Disorders Sales by Country (2018-2023) & (K Units)
• Table 61. US & Canada Drugs for Treating Metabolic Disorders Sales by Country (2024-2029) & (K Units)
• Table 62. Europe Drugs for Treating Metabolic Disorders Sales by Type (2018-2023) & (K Units)
• Table 63. Europe Drugs for Treating Metabolic Disorders Sales by Type (2024-2029) & (K Units)
• Table 64. Europe Drugs for Treating Metabolic Disorders Revenue by Type (2018-2023) & (US$ Million)
• Table 65. Europe Drugs for Treating Metabolic Disorders Revenue by Type (2024-2029) & (US$ Million)
• Table 66. Europe Drugs for Treating Metabolic Disorders Sales by Application (2018-2023) & (K Units)
• Table 67. Europe Drugs for Treating Metabolic Disorders Sales by Application (2024-2029) & (K Units)
• Table 68. Europe Drugs for Treating Metabolic Disorders Revenue by Application (2018-2023) & (US$ Million)
• Table 69. Europe Drugs for Treating Metabolic Disorders Revenue by Application (2024-2029) & (US$ Million)
• Table 70. Europe Drugs for Treating Metabolic Disorders Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
• Table 71. Europe Drugs for Treating Metabolic Disorders Revenue by Country (2018-2023) & (US$ Million)
• Table 72. Europe Drugs for Treating Metabolic Disorders Revenue by Country (2024-2029) & (US$ Million)
• Table 73. Europe Drugs for Treating Metabolic Disorders Sales by Country (2018-2023) & (K Units)
• Table 74. Europe Drugs for Treating Metabolic Disorders Sales by Country (2024-2029) & (K Units)
• Table 75. China Drugs for Treating Metabolic Disorders Sales by Type (2018-2023) & (K Units)
• Table 76. China Drugs for Treating Metabolic Disorders Sales by Type (2024-2029) & (K Units)
• Table 77. China Drugs for Treating Metabolic Disorders Revenue by Type (2018-2023) & (US$ Million)
• Table 78. China Drugs for Treating Metabolic Disorders Revenue by Type (2024-2029) & (US$ Million)
• Table 79. China Drugs for Treating Metabolic Disorders Sales by Application (2018-2023) & (K Units)
• Table 80. China Drugs for Treating Metabolic Disorders Sales by Application (2024-2029) & (K Units)
• Table 81. China Drugs for Treating Metabolic Disorders Revenue by Application (2018-2023) & (US$ Million)
• Table 82. China Drugs for Treating Metabolic Disorders Revenue by Application (2024-2029) & (US$ Million)
• Table 83. Asia Drugs for Treating Metabolic Disorders Sales by Type (2018-2023) & (K Units)
• Table 84. Asia Drugs for Treating Metabolic Disorders Sales by Type (2024-2029) & (K Units)
• Table 85. Asia Drugs for Treating Metabolic Disorders Revenue by Type (2018-2023) & (US$ Million)
• Table 86. Asia Drugs for Treating Metabolic Disorders Revenue by Type (2024-2029) & (US$ Million)
• Table 87. Asia Drugs for Treating Metabolic Disorders Sales by Application (2018-2023) & (K Units)
• Table 88. Asia Drugs for Treating Metabolic Disorders Sales by Application (2024-2029) & (K Units)
• Table 89. Asia Drugs for Treating Metabolic Disorders Revenue by Application (2018-2023) & (US$ Million)
• Table 90. Asia Drugs for Treating Metabolic Disorders Revenue by Application (2024-2029) & (US$ Million)
• Table 91. Asia Drugs for Treating Metabolic Disorders Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
• Table 92. Asia Drugs for Treating Metabolic Disorders Revenue by Region (2018-2023) & (US$ Million)
• Table 93. Asia Drugs for Treating Metabolic Disorders Revenue by Region (2024-2029) & (US$ Million)
• Table 94. Asia Drugs for Treating Metabolic Disorders Sales by Region (2018-2023) & (K Units)
• Table 95. Asia Drugs for Treating Metabolic Disorders Sales by Region (2024-2029) & (K Units)
• Table 96. Middle East, Africa and Latin America Drugs for Treating Metabolic Disorders Sales by Type (2018-2023) & (K Units)
• Table 97. Middle East, Africa and Latin America Drugs for Treating Metabolic Disorders Sales by Type (2024-2029) & (K Units)
• Table 98. Middle East, Africa and Latin America Drugs for Treating Metabolic Disorders Revenue by Type (2018-2023) & (US$ Million)
• Table 99. Middle East, Africa and Latin America Drugs for Treating Metabolic Disorders Revenue by Type (2024-2029) & (US$ Million)
• Table 100. Middle East, Africa and Latin America Drugs for Treating Metabolic Disorders Sales by Application (2018-2023) & (K Units)
• Table 101. Middle East, Africa and Latin America Drugs for Treating Metabolic Disorders Sales by Application (2024-2029) & (K Units)
• Table 102. Middle East, Africa and Latin America Drugs for Treating Metabolic Disorders Revenue by Application (2018-2023) & (US$ Million)
• Table 103. Middle East, Africa and Latin America Drugs for Treating Metabolic Disorders Revenue by Application (2024-2029) & (US$ Million)
• Table 104. Middle East, Africa and Latin America Drugs for Treating Metabolic Disorders Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
• Table 105. Middle East, Africa and Latin America Drugs for Treating Metabolic Disorders Revenue by Country (2018-2023) & (US$ Million)
• Table 106. Middle East, Africa and Latin America Drugs for Treating Metabolic Disorders Revenue by Country (2024-2029) & (US$ Million)
• Table 107. Middle East, Africa and Latin America Drugs for Treating Metabolic Disorders Sales by Country (2018-2023) & (K Units)
• Table 108. Middle East, Africa and Latin America Drugs for Treating Metabolic Disorders Sales by Country (2024-2029) & (K Units)
• Table 109. Novo Nordisk Company Information
• Table 110. Novo Nordisk Description and Major Businesses
• Table 111. Novo Nordisk Drugs for Treating Metabolic Disorders Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
• Table 112. Novo Nordisk Drugs for Treating Metabolic Disorders Product Model Numbers, Pictures, Descriptions and Specifications
• Table 113. Novo Nordisk Recent Developments
• Table 114. Sanofi Company Information
• Table 115. Sanofi Description and Major Businesses
• Table 116. Sanofi Drugs for Treating Metabolic Disorders Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
• Table 117. Sanofi Drugs for Treating Metabolic Disorders Product Model Numbers, Pictures, Descriptions and Specifications
• Table 118. Sanofi Recent Developments
• Table 119. Eli Lilly and Company Company Information
• Table 120. Eli Lilly and Company Description and Major Businesses
• Table 121. Eli Lilly and Company Drugs for Treating Metabolic Disorders Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
• Table 122. Eli Lilly and Company Drugs for Treating Metabolic Disorders Product Model Numbers, Pictures, Descriptions and Specifications
• Table 123. Eli Lilly and Company Recent Developments
• Table 124. AstraZeneca Company Information
• Table 125. AstraZeneca Description and Major Businesses
• Table 126. AstraZeneca Drugs for Treating Metabolic Disorders Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
• Table 127. AstraZeneca Drugs for Treating Metabolic Disorders Product Model Numbers, Pictures, Descriptions and Specifications
• Table 128. AstraZeneca Recent Developments
• Table 129. Merck Company Information
• Table 130. Merck Description and Major Businesses
• Table 131. Merck Drugs for Treating Metabolic Disorders Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
• Table 132. Merck Drugs for Treating Metabolic Disorders Product Model Numbers, Pictures, Descriptions and Specifications
• Table 133. Merck Recent Developments
• Table 134. Johnson & Johnson Company Information
• Table 135. Johnson & Johnson Description and Major Businesses
• Table 136. Johnson & Johnson Drugs for Treating Metabolic Disorders Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
• Table 137. Johnson & Johnson Drugs for Treating Metabolic Disorders Product Model Numbers, Pictures, Descriptions and Specifications
• Table 138. Johnson & Johnson Recent Developments
• Table 139. Boehringer Ingelheim Company Information
• Table 140. Boehringer Ingelheim Description and Major Businesses
• Table 141. Boehringer Ingelheim Drugs for Treating Metabolic Disorders Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
• Table 142. Boehringer Ingelheim Drugs for Treating Metabolic Disorders Product Model Numbers, Pictures, Descriptions and Specifications
• Table 143. Boehringer Ingelheim Recent Developments
• Table 144. Gilead Sciences Company Information
• Table 145. Gilead Sciences Description and Major Businesses
• Table 146. Gilead Sciences Drugs for Treating Metabolic Disorders Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
• Table 147. Gilead Sciences Drugs for Treating Metabolic Disorders Product Model Numbers, Pictures, Descriptions and Specifications
• Table 148. Gilead Sciences Recent Developments
• Table 149. Key Raw Materials Lists
• Table 150. Raw Materials Key Suppliers Lists
• Table 151. Drugs for Treating Metabolic Disorders Distributors List
• Table 152. Drugs for Treating Metabolic Disorders Customers List
• Table 153. Drugs for Treating Metabolic Disorders Market Trends
• Table 154. Drugs for Treating Metabolic Disorders Market Drivers
• Table 155. Drugs for Treating Metabolic Disorders Market Challenges
• Table 156. Drugs for Treating Metabolic Disorders Market Restraints
• Table 157. Research Programs/Design for This Report
• Table 158. Key Data Information from Secondary Sources
• Table 159. Key Data Information from Primary Sources

List of Figures

• Figure 1. Drugs for Treating Metabolic Disorders Product Picture
• Figure 2. Global Drugs for Treating Metabolic Disorders Market Size Growth Rate by Type, 2018 VS 2022 VS 2029 (US$ Million)
• Figure 3. Global Drugs for Treating Metabolic Disorders Market Share by Type in 2022 & 2029
• Figure 4. Antidiabetic Drugs Product Picture
• Figure 5. Antihypertensive Drugs Product Picture
• Figure 6. Hypolipidemic Drugs Product Picture
• Figure 7. Others Product Picture
• Figure 8. Global Drugs for Treating Metabolic Disorders Market Size Growth Rate by Application, 2018 VS 2022 VS 2029 (US$ Million)
• Figure 9. Global Drugs for Treating Metabolic Disorders Market Share by Application in 2022 & 2029
• Figure 10. Hospital
• Figure 11. Pharmacy
• Figure 12. Drugs for Treating Metabolic Disorders Report Years Considered
• Figure 13. Global Drugs for Treating Metabolic Disorders Revenue, (US$ Million), 2018 VS 2022 VS 2029
• Figure 14. Global Drugs for Treating Metabolic Disorders Revenue 2018-2029 (US$ Million)
• Figure 15. Global Drugs for Treating Metabolic Disorders Revenue Market Share by Region in Percentage: 2022 Versus 2029
• Figure 16. Global Drugs for Treating Metabolic Disorders Revenue Market Share by Region (2018-2029)
• Figure 17. Global Drugs for Treating Metabolic Disorders Sales 2018-2029 ((K Units)
• Figure 18. Global Drugs for Treating Metabolic Disorders Sales Market Share by Region (2018-2029)
• Figure 19. US & Canada Drugs for Treating Metabolic Disorders Sales YoY (2018-2029) & (K Units)
• Figure 20. US & Canada Drugs for Treating Metabolic Disorders Revenue YoY (2018-2029) & (US$ Million)
• Figure 21. Europe Drugs for Treating Metabolic Disorders Sales YoY (2018-2029) & (K Units)
• Figure 22. Europe Drugs for Treating Metabolic Disorders Revenue YoY (2018-2029) & (US$ Million)
• Figure 23. China Drugs for Treating Metabolic Disorders Sales YoY (2018-2029) & (K Units)
• Figure 24. China Drugs for Treating Metabolic Disorders Revenue YoY (2018-2029) & (US$ Million)
• Figure 25. Asia (excluding China) Drugs for Treating Metabolic Disorders Sales YoY (2018-2029) & (K Units)
• Figure 26. Asia (excluding China) Drugs for Treating Metabolic Disorders Revenue YoY (2018-2029) & (US$ Million)
• Figure 27. Middle East, Africa and Latin America Drugs for Treating Metabolic Disorders Sales YoY (2018-2029) & (K Units)
• Figure 28. Middle East, Africa and Latin America Drugs for Treating Metabolic Disorders Revenue YoY (2018-2029) & (US$ Million)
• Figure 29. The Drugs for Treating Metabolic Disorders Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2022
• Figure 30. The Top 5 and 10 Largest Manufacturers of Drugs for Treating Metabolic Disorders in the World: Market Share by Drugs for Treating Metabolic Disorders Revenue in 2022
• Figure 31. Global Drugs for Treating Metabolic Disorders Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022
• Figure 32. Global Drugs for Treating Metabolic Disorders Sales Market Share by Type (2018-2029)
• Figure 33. Global Drugs for Treating Metabolic Disorders Revenue Market Share by Type (2018-2029)
• Figure 34. Global Drugs for Treating Metabolic Disorders Sales Market Share by Application (2018-2029)
• Figure 35. Global Drugs for Treating Metabolic Disorders Revenue Market Share by Application (2018-2029)
• Figure 36. US & Canada Drugs for Treating Metabolic Disorders Sales Market Share by Type (2018-2029)
• Figure 37. US & Canada Drugs for Treating Metabolic Disorders Revenue Market Share by Type (2018-2029)
• Figure 38. US & Canada Drugs for Treating Metabolic Disorders Sales Market Share by Application (2018-2029)
• Figure 39. US & Canada Drugs for Treating Metabolic Disorders Revenue Market Share by Application (2018-2029)
• Figure 40. US & Canada Drugs for Treating Metabolic Disorders Revenue Share by Country (2018-2029)
• Figure 41. US & Canada Drugs for Treating Metabolic Disorders Sales Share by Country (2018-2029)
• Figure 42. U.S. Drugs for Treating Metabolic Disorders Revenue (2018-2029) & (US$ Million)
• Figure 43. Canada Drugs for Treating Metabolic Disorders Revenue (2018-2029) & (US$ Million)
• Figure 44. Europe Drugs for Treating Metabolic Disorders Sales Market Share by Type (2018-2029)
• Figure 45. Europe Drugs for Treating Metabolic Disorders Revenue Market Share by Type (2018-2029)
• Figure 46. Europe Drugs for Treating Metabolic Disorders Sales Market Share by Application (2018-2029)
• Figure 47. Europe Drugs for Treating Metabolic Disorders Revenue Market Share by Application (2018-2029)
• Figure 48. Europe Drugs for Treating Metabolic Disorders Revenue Share by Country (2018-2029)
• Figure 49. Europe Drugs for Treating Metabolic Disorders Sales Share by Country (2018-2029)
• Figure 50. Germany Drugs for Treating Metabolic Disorders Revenue (2018-2029) & (US$ Million)
• Figure 51. France Drugs for Treating Metabolic Disorders Revenue (2018-2029) & (US$ Million)
• Figure 52. U.K. Drugs for Treating Metabolic Disorders Revenue (2018-2029) & (US$ Million)
• Figure 53. Italy Drugs for Treating Metabolic Disorders Revenue (2018-2029) & (US$ Million)
• Figure 54. Russia Drugs for Treating Metabolic Disorders Revenue (2018-2029) & (US$ Million)
• Figure 55. China Drugs for Treating Metabolic Disorders Sales Market Share by Type (2018-2029)
• Figure 56. China Drugs for Treating Metabolic Disorders Revenue Market Share by Type (2018-2029)
• Figure 57. China Drugs for Treating Metabolic Disorders Sales Market Share by Application (2018-2029)
• Figure 58. China Drugs for Treating Metabolic Disorders Revenue Market Share by Application (2018-2029)
• Figure 59. Asia Drugs for Treating Metabolic Disorders Sales Market Share by Type (2018-2029)
• Figure 60. Asia Drugs for Treating Metabolic Disorders Revenue Market Share by Type (2018-2029)
• Figure 61. Asia Drugs for Treating Metabolic Disorders Sales Market Share by Application (2018-2029)
• Figure 62. Asia Drugs for Treating Metabolic Disorders Revenue Market Share by Application (2018-2029)
• Figure 63. Asia Drugs for Treating Metabolic Disorders Revenue Share by Region (2018-2029)
• Figure 64. Asia Drugs for Treating Metabolic Disorders Sales Share by Region (2018-2029)
• Figure 65. Japan Drugs for Treating Metabolic Disorders Revenue (2018-2029) & (US$ Million)
• Figure 66. South Korea Drugs for Treating Metabolic Disorders Revenue (2018-2029) & (US$ Million)
• Figure 67. China Taiwan Drugs for Treating Metabolic Disorders Revenue (2018-2029) & (US$ Million)
• Figure 68. Southeast Asia Drugs for Treating Metabolic Disorders Revenue (2018-2029) & (US$ Million)
• Figure 69. India Drugs for Treating Metabolic Disorders Revenue (2018-2029) & (US$ Million)
• Figure 70. Middle East, Africa and Latin America Drugs for Treating Metabolic Disorders Sales Market Share by Type (2018-2029)
• Figure 71. Middle East, Africa and Latin America Drugs for Treating Metabolic Disorders Revenue Market Share by Type (2018-2029)
• Figure 72. Middle East, Africa and Latin America Drugs for Treating Metabolic Disorders Sales Market Share by Application (2018-2029)
• Figure 73. Middle East, Africa and Latin America Drugs for Treating Metabolic Disorders Revenue Market Share by Application (2018-2029)
• Figure 74. Middle East, Africa and Latin America Drugs for Treating Metabolic Disorders Revenue Share by Country (2018-2029)
• Figure 75. Middle East, Africa and Latin America Drugs for Treating Metabolic Disorders Sales Share by Country (2018-2029)
• Figure 76. Brazil Drugs for Treating Metabolic Disorders Revenue (2018-2029) & (US$ Million)
• Figure 77. Mexico Drugs for Treating Metabolic Disorders Revenue (2018-2029) & (US$ Million)
• Figure 78. Turkey Drugs for Treating Metabolic Disorders Revenue (2018-2029) & (US$ Million)
• Figure 79. Israel Drugs for Treating Metabolic Disorders Revenue (2018-2029) & (US$ Million)
• Figure 80. GCC Countries Drugs for Treating Metabolic Disorders Revenue (2018-2029) & (US$ Million)
• Figure 81. Drugs for Treating Metabolic Disorders Value Chain
• Figure 82. Drugs for Treating Metabolic Disorders Production Process
• Figure 83. Channels of Distribution
• Figure 84. Distributors Profiles
• Figure 85. Bottom-up and Top-down Approaches for This Report
• Figure 86. Data Triangulation
• Figure 87. Key Executives Interviewed